858 Therapeutics website screenshot

858 Therapeutics

858 Therapeutics is a clinical-stage biotechnology company based in San Diego, California, developing first-in-class and best-in-class small-molecule therapies that target tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral, potent, and selective PARG (poly(ADP-ribose) glycohydrolase) inhibitor being evaluated in a Phase 1/2 study for patients with advanced solid tumors, exploiting cancer-cell vulnerabilities tied to replication stress and defects in replication-fork protection. The company was surfaced as a portfolio company of Insight Partners and added to the API Evangelist network. As a clinical-stage therapeutics company it publishes a corporate and scientific web presence but no public developer, API, or documentation surface, so API artifacts are not applicable.

858 Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech, Therapeutics, Oncology, and Precision Medicine.

858 Therapeutics’ developer surface includes engineering blog, support, and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechTherapeuticsOncologyPrecision MedicineDrug DiscoveryDNA Damage ResponseClinical StagePharmaceuticals

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.1/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/858-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

858 Therapeutics Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: 858-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/858-therapeutics.png
name: 858 Therapeutics
description: 858 Therapeutics is a clinical-stage biotechnology company based in San Diego, California, developing first-in-class
  and best-in-class small-molecule therapies that target tumor dependencies in DNA damage response (DDR) pathways. Its lead
  program, ETX-19477, is an oral, potent, and selective PARG (poly(ADP-ribose) glycohydrolase) inhibitor being evaluated in
  a Phase 1/2 study for patients with advanced solid tumors, exploiting cancer-cell vulnerabilities tied to replication stress
  and defects in replication-fork protection. The company was surfaced as a portfolio company of Insight Partners and added
  to the API Evangelist network. As a clinical-stage therapeutics company it publishes a corporate and scientific web presence
  but no public developer, API, or documentation surface, so API artifacts are not applicable.
url: https://raw.githubusercontent.com/api-evangelist/858-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biotech
- Therapeutics
- Oncology
- Precision Medicine
- Drug Discovery
- DNA Damage Response
- Clinical Stage
- Pharmaceuticals
apis: []
common:
- type: Website
  url: https://8five8tx.com/
- type: Blog
  url: https://8five8tx.com/news/
- type: Support
  url: https://8five8tx.com/contact/
- type: DomainSecurity
  url: security/858-therapeutics-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence